Search Result

Isoforms Recommended:	apoB

Results for "

apoB

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apolipoprotein (7) Bacterial (1) Endogenous Metabolite (6) HCV (2) Hedgehog (1) LDLR (1) Microsomal Triglyceride Transfer Protein (MTP) (1) Small Interfering RNA (siRNA) (3) Smo (1)
By Research Areas:	Cancer (1) Cardiovascular Disease (6) Infection (1) Metabolic Disease (6)
Oligonucleotides:	Nucleosides and their Analogs (1) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) Antisense Oligonucleotides (2) Uracil (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W588264

3-Iodo-L-thyronine 3-Monoiodothyronine	Apolipoprotein Endogenous Metabolite	Metabolic Disease
3-Iodo-L-thyronine (3-Monoiodothyronine) is a thyroid hormone metabolite. 3-iodo-L-thyronine can bind to apolipoprotein B-100 (apoB-100) .

HY-108764

Mipomersen sodium 1 Publications Verification ISIS 301012	Apolipoprotein HCV	Metabolic Disease
Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B *(apoB). Mipomersen has anti-HCV* effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-P10188

apoB (4372-4392)	Apolipoprotein	Cardiovascular Disease
apoB (4372-4392) is a potent lipoprotein(a) assembly inhibitor, with an IC₅₀ of 40 μM. apoB (4372-4392) can noncovalently bind to apolipoprotein(a) with high affinity .

HY-RS24199

Apob Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Apob Rat Pre-designed siRNA Set A contains three designed siRNAs for Apob gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Apob Rat Pre-designed siRNA Set A Apob Rat Pre-designed siRNA Set A

HY-RS00833

APOB Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
APOB Human Pre-designed siRNA Set A contains three designed siRNAs for APOB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

APOB Human Pre-designed siRNA Set A APOB Human Pre-designed siRNA Set A

HY-RS17734

Apob Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Apob Mouse Pre-designed siRNA Set A contains three designed siRNAs for Apob gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Apob Mouse Pre-designed siRNA Set A Apob Mouse Pre-designed siRNA Set A

HY-171464

Lp(a)-IN-5	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and *ApoB* proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases .

HY-171464A

Lp(a)-IN-5 hydrochloride	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-5 (Compound A) hydrochloride is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 hydrochloride inhibits the assembly of Apo(a) and *ApoB* proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 hydrochloride is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases .

HY-177291

LAB687	Microsomal Triglyceride Transfer Protein (MTP) Smo Hedgehog	Cardiovascular Disease Cancer
LAB687 (Compound 2a) is a Microsomal triglyceride transfer protein (MTP) inhibitor with an IC₅₀ of 0.9  nM for the secretion of apoB from HepG2 cells. LAB687 is also a Smoothened (Smo) antagonist with IC₅₀s of 2.48 and 3.42 μM for mouse and human Smo receptor, respectively. LAB687 can lower the level of triglycerides and LDL cholesterol and inhibits the Hedgehog signaling pathway .

HY-173323

Lp(a)-IN-7	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-7 (example 1) is a lipoprotein (a) (Lp(a)) formation inhibitor with an IC₅₀ of 2.51 nM in conditioned media containing apolipoprotein B (apoB) and apolipoprotein(a). Lp(a)-IN-7 can be used for the study of cardiovascular disease .

HY-148647

Mipomersen 1 Publications Verification ISIS 301012 free base	Apolipoprotein HCV	Infection
Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B *(apoB). Mipomersen has anti-HCV* effect and reduces the infectivity of the HCV. Mipomersen can be used for the research of homozygous familial hypercholesterolemia (HoFH) .

HY-152857

Muvalaplin LY3473329	LDLR	Cardiovascular Disease
Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a) formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys .

HY-W011824

2′-O-Methyluridine	Bacterial Endogenous Metabolite	Others
2’-O-Methyluridine is a modified nucleoside that can be found in T. thermophile tRNA. 2’-O-Methyluridine can be incorporated into siRNA targeting the gene encoding apolipoprotein B, which decreases ApoB protein levels in HepG2 and prevents IFN-α production in isolated human PBMCs. 2’-O-Methyluridine level in serum is decreased in patients with breast cancer .

HY-112540

Acetoacetic acid	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid can be used to study metabolic diseases .

HY-112540B

Acetoacetic acid sodium 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid sodium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid sodium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid sodium can be used to study metabolic diseases .

HY-112540A

Acetoacetic acid lithium 4 Publications Verification	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

HY-112540AR

Acetoacetic acid lithium (Standard)	Endogenous Metabolite	Metabolic Disease
Acetoacetic acid (lithium) (Standard) is the analytical standard of Acetoacetic acid (lithium). This product is intended for research and analytical applications. Acetoacetic acid lithium is an oxidative stress inducer that affects the antioxidant enzyme system and lipoprotein metabolism. Acetoacetic acid lithium induces oxidative stress by decreasing the mRNA expression and activity of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increasing MDA content, and inhibiting very low density lipoprotein (VLDL) assembly by downregulating apolipoprotein ApoB100, ApoE, and low density lipoprotein receptor (LDLR), leading to triglyceride (TG) accumulation in hepatocytes. Acetoacetic acid lithium can be used to study metabolic diseases .

Cat. No.	Product Name	Target	Research Area